The company website lists a confidential monoclonal antibody with a market cap of >1billion.
At the shareholders meeting, I asked about the confidential monoclonal antibody. The confidential mAb was disclosed as fully humanized. Great.
Palivizumab is a fully humanized mAb with annual sales slightly over 1billion made by astrazeneca, medimmune. While sales continue to grow, they are growing at a declining rate. Astrazeneca also discontinued and withdrew BLA for Motavizumab.
download of cost/benefit analysis for Palivizumab:
The recent decline in US sales can be attributed to the adoption of new guidelines published by the American Academy of Pediatrics restricting the usage of Synagis (palivizumab) at the start of the 2009/2010 RSV season.
Dr Yusibov has done extensive research on this related topic and has several publications, citations, etc on this related material. Fraunhofer also has done extensive research into related biological function.
vaccine march 2005
...etc, etc al there are more research publications with broader spectrum application for similarly related function
Astrazeneca and Fraunhofer (germany) have strong, multi-faceted and diverse relationship
The world infection market is valued at $82 billion, with anti-bacterials accounting for approximately 46%, anti-virals for 29% and vaccines 13%.
Julian, great to see you posting. I been tied up over at arna today, shorts put out negative article and then did a bear raid. I trying to console longs over there, some get easily spooked and sell. I have to tell you, I have spread the word about ibio, I feel obligated to if I know they can gain from it. I also tell them that you are sole source on this board for dd. Obviously, most newbies are not versed in this technology. They will be looking to you for knowledge. Thanks, have a great day
Cases of anaphylaxis and anaphylactic shock, including fatal cases, have been reported following initial exposure or re-exposure to Synagis. Severe acute hypersensitivity reactions have also been reported on initial exposure or re-exposure to Synagis.
These side effects due to allergic reactions are obsolete using the ibiolaunch to overcome inherent limitations.
Also, see Crucells work in the area of rabies vaccines and treatment post-exposure and cross reference with the earlier work of Dy yusibov on the same topic. I think there is a worthwhile business opportunity to be explored with the leveraging of current relationships and insights provided.
Journal of Virology 2010, 2011- applied to co expression of multiple expression and x-reference with Crucell's application for post-exposure cocktail treatment of rabies.
About Crucell's rabies monoclonal antibody program
Crucell's rabies monoclonal antibody product is a combination of two human monoclonal antibodies, generated using Crucell's MAbstract® technology and produced using Crucell's PER.C6® technology. Crucell's rabies monoclonal antibody combination offers the potential to replace the traditional serum-derived products that are currently used for rabies post-exposure prophylaxis. Phase I clinical trials data conducted in the United States and India supported further clinical development. The program has been granted a Fast Track designation by the US Food and Drug Administration's (FDA) Department of Health and Human Services in February 2008. The Fast Track program facilitates the development and expedites the review of new drugs that are intended to treat serious or life-threatening diseases and that demonstrate the potential to address unmet medical needs.
In December 2007, Crucell and Sanofi Pasteur signed an exclusive collaboration and commercialization agreement for Crucell's rabies monoclonal antibodies, next-generation rabies biologicals, to be used with rabies vaccine for post-exposure prophylaxis against this fatal disease. Under the terms of the agreement, Crucell will continue to perform the development activities. Crucell will be responsible for the manufacturing of the final product and will retain exclusive distribution rights in Europe, co-exclusive distribution rights in China and the rights to sell to supranational organizations such as UNICEF. Crucell received an initial payment of €10 million following the execution of the agreement and will be eligible for milestone payments of up to €66.5 million.
About PER.C6® technology
Crucell's PER.C6® technology is a cell line developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies. The strengths of the PER.C6® technology lie in its safety profile, scalability and productivity under serum-free culture conditions.
About MAbstract® technology
Crucell's proprietary MAbstract® technology can be used to discover drug targets, such as cancer markers or proteins from infectious agents including bacteria and viruses, and identify human antibodies against those drug targets.
I find it very interesting that when researching other companies, i see parallels to Yusibov research and potential opportunities pertaining to IBIO that strengthen my belief in the significant demand for the generalized and specific deployment of the ibiolaunch, and that same research provides for the effectiveness of the application of the ibiolaunch produced candidate.
medicago is working on a rabies vaccine, and using some of Dr Yusibov's earlier research as a foundation, from what i can gather.
here is another ot article fwiw
cross reference this with some of the docs i posted over the last couple of weeks, filovirus grant terms, priorities of DOD as they pertain to new budget in this area